Trials of combinations of PD-1 inhibitors with other targeted therapies such as PI3K inhibitors, guided by molecular markers such as PIK3CA mutations, should be considered as one of the next steps of cervical cancer therapeutics. The gene discussed is PIK3CA; the disease is cervical carcinoma.